

Pall Ultipor® 100

Breathing System Filter

- Pleated hydrophobic membrane
- High efficiency bacterial and viral filtration
- Smooth housing profile
- Optimal humidification
- Compatible with nebulization
- 100% retentive for liquid-borne contaminants
- Retains natural rubber latex allergens in solutions and in airborne particles
- Individually integrity and efficiency tested during manufacture



- **Optimal humidification:** Physiological levels of humidification are maintained, even at high flow rates and in long term ventilation. Clinical humidification performance is comparable to hot water bath systems and hygroscopic HMEs ^{1,2,3,4}. Rheological and physical properties of patient airway mucus are preserved and physiological mucus clearance is maintained ⁵.
- Compatible with nebulization: Medications can be nebulised between the filter and the patient.
 - hydrophobic barrier: The pleated hydrophobic membrane provides effective protection against airborne and liquid-borne micro-organisms. This assures protection against cross-contamination between patients in anaesthesia 6,7,8 and can contribute to a reduction of ventilator associated pneumonia in long term intensive care ventilation 4. The filter has been validated to remove *Mycobacterium tuberculosis* 9, *Staphylococcus aureus* 10, Hepatitis C virus 7 and HIV 11 and Influenza A Virus 12. All Pall Breathing System Filters contain the proprietary Pall fine hydrophobic filter media, which has been tested in manufacturing to show a water intrusion pressure (hydrophobicity) in excess of 50 cm water column.

Routine use of the Ultipor 100 will protect the interior of the breathing system from patient derived contamination, allowing extended use of the breathing system in conjunction with a hospital protocol that



ensures hygienic and mechanical integrity of the system. Please refer to your breathing system manufacturer for information on whether the system being used has been validated for extended use.

- Extended life: When nebulization is not used.
- Latex safety: The Ultipor 100 filter is not made with natural rubber latex. It it has been tested to show retention of natural rubber latex allergens in liquids and contained in airborne particles 13,14.

Pall Total Quality and Performance Guarantee

Each Pall Ultipor 100 Breathing System Filter is individually tested during manufacture for:

Filter Integrity - assuring housing and seal quality.

Filtration Efficiency - using a non-destructive test, assuring membrane quality.

A Product Validation Certificate that is batch and customer specific can be provided to show details of testing and validation. This is the customer's guarantee of 100% reliability, performance in use and assurance of protection of breathing systems and equipment, patients and staff.

Pall Ultipor 100 Performance

Specifications

Filter material

Pleated hydrophobic membrane

Liquid-borne bacterial/viral removal efficiency 100%

Bacterial / viral aerosol removal efficiency

> 99.999% / 99.999%

NaCl penetration (ISO23328-1: 2003):

0.006%

Humidification

Water loss: 8 mg/L up to 800 mL tidal volume Water loss: 9.5 mg/L @ 800 – 1000 mL tidal volume

Resistance at 60 L/min

Approximately 2 cm water column

Construction

Transparent, non-conductive

Connections (ISO tapers)

Patient side 15 mm ID 22 mm OD Breathing system side 22 mm ID

Filter volume

Approximately 85 mL

Weight

Approximately 47 g

Recommended use

24 hr change. Use may be extended to 48 hr when nebulisation is not used. Single use, patient end only

Ordering Information

Reorder Code	Description	Packaging
BB100A	Pall Ultipor 100 Breathing System Filter	50 units per case
BB100AF	Pall Ultipor 100 Breathing System Filter with Flex tube	50 units per case

References

- 1. F Tiger et al. Journal de la Société Francophone d'Urgences Médicales et de la Société de Réanimation de Langue Française 1994; 3: 6.
- 2. Nakagawa NK et al. Clinical Intensive Care 1995; 6: 2 supplement.
- 3. Martin C et al. Presented at the ATS/ALA meeting, Seattle USA, May 1995.
- Kirton OC et al. Chest 1997; 112: 1055-59
- 5. Nakagawa NK et al. Crit Care Med 2000; 28(2): 312-317
- 6. Association of Anaesthetists of Great Britain and Ireland. HIV and other blood borne viruses - guidance for anaesthetists. January 1996 Update.
- 7. Lloyd G et al. Anaesthesia and Intensive Care 1997; 25: 235-38.
- Purday J. Technic 1997; 63: 9-11.
- 9. Speight S et al. Centre for Applied Microbiology and Research, 1995.
- 10. Rosales M & Dominguez V. 2nd International Conference on Prevention of Infection. Nice, France, 4-5th May 1992.
- 11. Lloyd G et al. Centre for Applied Microbiology and Research, 1997.
- 12. Heuer et al. GMS Hyg Infect Control. 2013 Apr 29;8(1)
- 13. Barbara J et al. Anaesthesia 2001; 56: 231-234.
- 14. Chen Z. Capewell A. Pall SLS Technical Report 2000.



Pall Corporate Headquarters

25 Harbor Park Drive Port Washington, NY 11050 Visit us on the Web at www.pall.com/medical

International Offices
Pall Corporation has offices and plants throughout the world in locations such as: Argentina, Australia, Australia, Pall Corporation has offices and plants throughout the Netherlands, New Zealand, Norway, Poland, Puerto Rico, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, the United States and Venezuela. Distributors in all major industrial areas of the world.

The information provided in this literature was reviewed for accuracy at the time of publication. Product data may be subject to change without notice. For current information consult your local Pall distributor or contact Pall directly.

© 2019, Pall Europe. Pall, was and Ultipor are trademarks of Pall Corporation.

® indicates a registered trademark in the USA. Protect What Matters - Every Day is a service mark of Pall Corporation.